TRL345 Antibody for Healthy Volunteers

"Affirmative, the information found on clinicaltrials.gov indicates that this trial is still open to participants and has been since September 14th 2023. The experiment requires a total of 16 individuals at 1 site."

"Affirmative, the information on clinicaltrials.gov demonstrates that this trial is presently enrolling individuals. This research project was initially published on September 14th 2023 and has been recently updated on the same date. It requires 16 subjects at a single centre for completion of its objectives."

"This trial has an age restriction that applicants must meet before being eligible, with the minimum age of admittance set at 18 and the upper limit capped at 65."

"Trellis Bioscience LLC, the clinical trial's sponsor, has stated that their primary measure of success over 11 weeks is assessing abnormal heart rate readings. Additionally, secondary outcomes such as Cmax and Cmin values determined by ELISA tests will be used to characterize a single intravenous infusion of TRL345."

"Due to the lack of clinical data on safety and efficacy, Dose Level 2 - 10 mg/kg received a score of 1."

"This clinical trial is recruiting for 16 healthy individuals between the age of 18-65. Candidates must fulfill the following prerequisites: Be a nonpregnant, nonbreastfeeding adult representative of general population; Give written informed consent and availability throughout study duration; Pass health assessments done at Screening Visit as judged by PI or delegatee; For WOCBP practice highly effective contraception from 28 days before screening to Day 76 - this may include abstinence, monogamous relationship with vasectomized partner, hormonal methods etc.; Men also must refrain from donating sperm during that time period."